FDA greenlight for Bayer’s AMBELVIST reshapes MRI contrast dosing

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 6:39 PM ET. Details in the imprint.

Bayer’s AMBELVIST (gadoquatrane) moves straight into the MRI spotlight this week after winning US FDA approval as a new macrocyclic gadolinium-based contrast agent for brain and body imaging in adults and pediatric patients, including term neonates. With a recommended dose of 0.01 mmol/kg actual body weight that delivers 0.04 mmol gadolinium per kilogram, the product debuts as the lowest-dose macrocyclic gadolinium-based contrast agent currently approved in the US, using 60 percent less gadolinium than agents dosed at 0.1 mmol/kg and 20 percent less than gadopiclenol at 0.05 mmol/kg according to Bayer’s announcement. The company’s US press release details the indication, dosing and comparative gadolinium load.

What AMBELVIST is designed to do in MRI suites

AMBELVIST is indicated for contrast-enhanced magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system - including brain, spine and associated tissues - as well as in non-CNS regions such as head and neck, thorax, abdomen, pelvis and musculoskeletal system in adult and pediatric patients, down to term neonates. The agent belongs to the class of macrocyclic gadolinium-based contrast agents (mGBCAs), which are favored by many radiologists because their chelate structure tightly binds gadolinium ions, and its low recommended dose is aimed at reducing overall gadolinium exposure while maintaining diagnostic image quality according to the product information. The US prescribing information outlines the full indication, dosing recommendations and safety profile.

From a workflow perspective, Bayer positions AMBELVIST as part of a broader radiology ecosystem that includes the company’s injectors, informatics and existing contrast portfolio, so hospitals and imaging centers can standardize protocols across brain and whole-body MRI. Clinical data submitted to the FDA showed that AMBELVIST-enhanced MRI allowed radiologists to detect and visualize CNS and non-CNS lesions with abnormal vascularity at doses lower in gadolinium content than selected approved comparators, while the most frequently reported adverse reactions in trials - such as headache, dizziness, injection site reactions, nausea, vomiting, feeling hot, paresthesia and pruritus - occurred in at least 0.2 percent of patients and were generally mild to moderate. Independent coverage of the approval notes that the launch adds a new low-dose macrocyclic option for US imaging providers who are increasingly attentive to gadolinium retention questions and contrast stewardship. A report in the Las Vegas Sun summarizes the FDA decision and clinical positioning.

For Bayer’s radiology business, AMBELVIST broadens a portfolio that already includes multiple contrast agents and injection systems used worldwide, giving the company another branded asset in a US MRI market that conducts tens of millions of scans per year across neurology, oncology and musculoskeletal indications. The product is part of Bayer’s Pharmaceuticals division, which the company has identified as a core growth pillar alongside Consumer Health and Crop Science, and management has repeatedly highlighted radiology as a strategic focus area in recent presentations. On the capital markets side, shares of Bayer AG (DE000BAY0017) last traded on Xetra in Frankfurt at EUR 29.37 on 06/14/2026, reflecting investor scrutiny of the group’s pipeline and litigation exposure even as new products like AMBELVIST come to market.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.